Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Entrada Therapeutics (TRDA) EBT (2022 - 2025)

Historic EBT for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to -$43.5 million.

  • Entrada Therapeutics' EBT fell 17359.68% to -$43.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$104.5 million, marking a year-over-year decrease of 23663.51%. This contributed to the annual value of $66.5 million for FY2024, which is 44958.68% up from last year.
  • Entrada Therapeutics' EBT amounted to -$43.5 million in Q3 2025, which was down 17359.68% from -$42.9 million recorded in Q2 2025.
  • Over the past 5 years, Entrada Therapeutics' EBT peaked at $57.8 million during Q2 2024, and registered a low of -$43.5 million during Q3 2025.
  • Its 4-year average for EBT is -$8.0 million, with a median of -$15.9 million in 2024.
  • The largest annual percentage gain for Entrada Therapeutics' EBT in the last 5 years was 91098.3% (2024), contrasted with its biggest fall of 18798.1% (2024).
  • Quarter analysis of 4 years shows Entrada Therapeutics' EBT stood at -$24.6 million in 2022, then surged by 137.52% to $9.2 million in 2023, then plummeted by 107.83% to -$724000.0 in 2024, then tumbled by 5905.52% to -$43.5 million in 2025.
  • Its EBT stands at -$43.5 million for Q3 2025, versus -$42.9 million for Q2 2025 and -$17.3 million for Q1 2025.